These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 20368727)

  • 21. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
    Sofeu CL; Rondeau V
    PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency.
    Maeda H; Kurokawa T
    Ann Oncol; 2015 Jan; 26(1):211-216. PubMed ID: 25361994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.
    Ciani O; Buyse M; Drummond M; Rasi G; Saad ED; Taylor RS
    Value Health; 2017 Mar; 20(3):487-495. PubMed ID: 28292495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.
    Inker LA; Mondal H; Greene T; Masaschi T; Locatelli F; Schena FP; Katafuchi R; Appel GB; Maes BD; Li PK; Praga M; Del Vecchio L; Andrulli S; Manno C; Gutierrez E; Mercer A; Carroll KJ; Schmid CH; Levey AS
    Am J Kidney Dis; 2016 Sep; 68(3):392-401. PubMed ID: 27032886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.
    Greene T; Ying J; Vonesh EF; Tighiouart H; Levey AS; Coresh J; Herrick JS; Imai E; Jafar TH; Maes BD; Perrone RD; Del Vecchio L; Wetzels JFM; Heerspink HJL; Inker LA
    J Am Soc Nephrol; 2019 Sep; 30(9):1756-1769. PubMed ID: 31292198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.
    Shi Q; Sargent DJ
    Int J Clin Oncol; 2009 Apr; 14(2):102-11. PubMed ID: 19390940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research priorities in biomarkers and surrogate end-points.
    Aronson JK
    Br J Clin Pharmacol; 2012 Jun; 73(6):900-7. PubMed ID: 22360291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surrogate end points in heart failure.
    Anand IS; Florea VG; Fisher L
    J Am Coll Cardiol; 2002 May; 39(9):1414-21. PubMed ID: 11985901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
    Weir CJ; Walley RJ
    Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.
    Ciani O; Buyse M; Drummond M; Rasi G; Saad ED; Taylor RS
    Nat Rev Drug Discov; 2016 Jul; 15(7):516. PubMed ID: 27256477
    [No Abstract]   [Full Text] [Related]  

  • 36. Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria.
    Heller G
    Ann Oncol; 2015 Oct; 26(10):2012-6. PubMed ID: 26254442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
    J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in surrogate threshold effect estimates between original and simplified correlation-based validation approaches.
    Schürmann C; Sieben W
    Stat Med; 2016 Mar; 35(7):1049-62. PubMed ID: 26522510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surrogate End Points and Their Validation in Oncology Clinical Trials.
    Zhao F
    J Clin Oncol; 2016 May; 34(13):1436-7. PubMed ID: 26951314
    [No Abstract]   [Full Text] [Related]  

  • 40. The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.
    Badve SV; Palmer SC; Strippoli GFM; Roberts MA; Teixeira-Pinto A; Boudville N; Cass A; Hawley CM; Hiremath SS; Pascoe EM; Perkovic V; Whalley GA; Craig JC; Johnson DW
    Am J Kidney Dis; 2016 Oct; 68(4):554-563. PubMed ID: 27138469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.